To determine the oncogenic effects of MKRN1-mediated inhibition of the PTEN tumour suppressor and activation of the PI3K/AKT pathway, we conducted a transwell migration assay using human cervical cancer cell lines (HeLa, ME-180 and CaSki). Here, MKRN1 is linked to neoplasm.